3/27
06:17 am
avbp
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? [Yahoo! Finance]
3/26
05:49 am
avbp
ArriVent BioPharma (AVBP) was upgraded by Truist Financial Corporation to "strong-buy".
Medium
Report
ArriVent BioPharma (AVBP) was upgraded by Truist Financial Corporation to "strong-buy".
3/24
07:13 am
avbp
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib [Seeking Alpha]
Low
Report
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib [Seeking Alpha]
3/23
12:27 pm
avbp
ArriVent BioPharma (AVBP) had its price target raised by B. Riley Financial, Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
ArriVent BioPharma (AVBP) had its price target raised by B. Riley Financial, Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.
3/17
05:45 pm
avbp
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Finance]
Medium
Report
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Finance]
3/17
05:34 pm
avbp
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 [Yahoo! Finance]
Medium
Report
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 [Yahoo! Finance]
3/17
05:00 pm
avbp
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
Medium
Report
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
3/17
05:00 pm
avbp
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Medium
Report
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
3/14
06:58 am
avbp
ArriVent BioPharma (AVBP) was upgraded by BTIG Research to "strong-buy".
Low
Report
ArriVent BioPharma (AVBP) was upgraded by BTIG Research to "strong-buy".
3/12
08:03 am
avbp
ArriVent BioPharma (AVBP) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Low
Report
ArriVent BioPharma (AVBP) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
3/11
02:18 pm
avbp
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Low
Report
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
3/6
12:25 pm
avbp
ArriVent BioPharma (AVBP) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $50.00 price target on the stock, up from $44.00.
Medium
Report
ArriVent BioPharma (AVBP) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $50.00 price target on the stock, up from $44.00.
3/6
11:34 am
avbp
ArriVent BioPharma (AVBP) had its price target raised by Citigroup Inc. from $31.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
ArriVent BioPharma (AVBP) had its price target raised by Citigroup Inc. from $31.00 to $33.00. They now have a "buy" rating on the stock.
3/6
08:03 am
avbp
ArriVent BioPharma (AVBP) had its price target raised by HC Wainwright from $42.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
ArriVent BioPharma (AVBP) had its price target raised by HC Wainwright from $42.00 to $44.00. They now have a "buy" rating on the stock.
3/5
04:31 pm
avbp
ArriVent BioPharma Reports Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
ArriVent BioPharma Reports Full Year 2025 Financial Results [Yahoo! Finance]
3/5
04:01 pm
avbp
ArriVent BioPharma Reports Full Year 2025 Financial Results
Medium
Report
ArriVent BioPharma Reports Full Year 2025 Financial Results
2/11
05:31 pm
avbp
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Medium
Report
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
2/11
05:31 pm
avbp
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Medium
Report
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
2/5
09:35 am
avbp
$207B Market Shift: The Race for Fast Track Approval in Oncology
Medium
Report
$207B Market Shift: The Race for Fast Track Approval in Oncology
1/23
05:06 am
avbp
ArriVent BioPharma (NASDAQ:AVBP) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
ArriVent BioPharma (NASDAQ:AVBP) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
10:35 am
avbp
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
Medium
Report
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026